BAKER BROS. ADVISORS LP
Q1 2025 13F Holdings
- Locationnew york, NY
- Num holdings
89
- Value ($000)
$9,036,702
- Date Filed05/15/2025
- Form type13F-HR
- CIK0001263508
- All SEC filings
- NoteHoldings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q1 2025 toSelect Quarter
Issuer Name | Class | CUSIP | VALUE | % | Shares | Principal | Option Type |
|---|---|---|---|---|---|---|---|
BGNE BeiGene, Ltd. | SPONSORED ADR | 07725L102 | $2.39B | 27 % | 8,799,053 | ||
INCY Incyte Corporation | COM | 45337C102 | $1.86B | 21 % | 30,739,953 | ||
ACAD ACADIA Pharmaceuticals Inc. | COM | 004225108 | $712.20M | 8 % | 42,877,916 | ||
MDGL Madrigal Pharmaceuticals, Inc. | COM | 558868105 | $654.04M | 7 % | 1,974,590 | ||
SMMT Summit Therapeutics Inc. | COM | 86627T108 | $471.16M | 5 % | 24,424,865 | ||
INSM Insmed Incorporated | COM PAR $.01 | 457669307 | $410.49M | 5 % | 5,380,626 | ||
RYTM Rhythm Pharmaceuticals, Inc. | COM | 76243J105 | $296.87M | 3 % | 5,604,483 | ||
RVMD Revolution Medicines, Inc. | COM | 76155X100 | $280.65M | 3 % | 7,936,972 | ||
KYMR Kymera Therapeutics, Inc. | COM | 501575104 | $164.11M | 2 % | 5,995,929 | ||
Alkermes plc | SHS | G01767105 | $148.04M | 2 % | 4,483,285 |
Rows Per Page
10
- 10
- 50
- 100